Role of leukotriene D4 in allergen-induced increases in airway smooth muscle in the rat.
The purpose of the study was to investigate whether allergen-induced hyperresponsiveness to methacholine and an increase in airway smooth muscle (ASM) in Brown Norway (BN) rats could be mediated by LTD4, an important mediator of allergic airway responses. Male BN rats, 8 to 12 wk of age, were sensitized with ovalbumin (OA). Rats were exposed 2 wk later to aerosols of saline (n = 6), OA (n = 8), or OA after pretreatment with the LTD4 antagonist MK-571 (2 mg/kg intraperitoneally, n = 9), on six occasions at 5-day intervals. Airway responsiveness to methacholine (the concentration required to double pulmonary resistance, EC200 RL) was measured immediately before the first aerosol exposure and 2 days after the last exposure. ASM was quantitated by morphometry, and areas were standardized for size using the epithelial basement membrane length (BM). Following OA challenges EC200 RL decreased from 6.5 to 3.1 mg/ml (p < 0.05) but did not change significantly after saline or OA exposures in MK-571-pretreated animals. ASM/BM2 in the large airways was significantly greater, 3.41 +/- 0.19 x 10(-3), after OA compared with 2.35 +/- 0.22 x 10(-3) for saline exposures (p < 0.01). The ASM/BM2 after OA exposures but with MK-571 pretreatment (2.75 +/- 0.25 x 10(-3)) was intermediate in value. The results indicate that both the increase in airway responsiveness and the increase in ASM following repeated antigen exposures appear to be mediated predominantly by LTD4.
Wang
C G
CG
Meakins-Christie Laboratories, McGill University, Montreal, Quebec, Canada.
Du
T
T
Xu
L J
LJ
Martin
J G
JG
D000403:Airway Resistance / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001485:Basement Membrane / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000494:pharmacology; D007114:Immunization; D008168:Lung / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D016210:Methacholine Chloride; D009130:Muscle, Smooth / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D010047:Ovalbumin / Q000008:administration & dosage / Q000009:adverse effects*; D011312:Pressure; D011422:Propionates / Q000494:pharmacology; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D012132:Respiratory Muscles / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000502:physiology*; D013997:Time Factors
D001993:Bronchodilator Agents; D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D013189:SRS-A; D016210:Methacholine Chloride; C059141:verlukast; D010047:Ovalbumin